Trial · NCT00732381
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)
NCT00732381, Phase 3, Completed, Organon and Co; results first posted 2009-11-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529). Trials, record NCT00732381. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00732381
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)
- NCT number
- NCT00732381
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 351 participants, actual
- Lead sponsor
- Organon and Co
- Conditions
- Allergic Rhinitis
- Interventions
- Mometasone furoate nasal spray (MFNS), Matching placebo nasal spray
- First posted
- 2008-08-12
- Last updated
- 2024-05-21
- Results first posted
- 2009-11-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days | 15 days of treatment | Nasal congestion was scored on a scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe symptoms. PRIOR (the subject's status over the previous 12 hours \[reflective\]) |
| Secondary | The Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days | 15 days of treatment | Total nasal symptom score (TNSS) is a composite of 4 symptoms, each is scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total can range from 0 to 12. PRIOR (the subject's status over the previous 12 hours \[reflective\]) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days | 15 days of treatment | The standard deviation is pooled. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | The Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days | 15 days of treatment | Units on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days | Mometasone Furoate Nasal Spray | -0.64 | Standard Deviation 0.52 | Units on a scale | |
| The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days | Placebo Nasal Spray | -0.49 | Standard Deviation 0.52 | Units on a scale | |
| The Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days | Mometasone Furoate Nasal Spray | -2.68 | Standard Deviation 2.01 | Units on a scale | |
| The Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days | Placebo Nasal Spray | -1.85 | Standard Deviation 2.01 | Units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mometasone Furoate Nasal Spray | 176 | |
| Overall Study | STARTED | Placebo Nasal Spray | 175 | |
| Overall Study | COMPLETED | Mometasone Furoate Nasal Spray | 174 | |
| Overall Study | COMPLETED | Placebo Nasal Spray | 174 | |
| Overall Study | NOT COMPLETED | Mometasone Furoate Nasal Spray | 2 | |
| Overall Study | NOT COMPLETED | Placebo Nasal Spray | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mometasone Furoate Nasal Spray | ||
| Total, all-cause mortality | Placebo Nasal Spray | ||
| Total, other adverse events | Mometasone Furoate Nasal Spray | 0 | 176 |
| Total, other adverse events | Placebo Nasal Spray | 0 | 175 |
| Total, serious adverse events | Mometasone Furoate Nasal Spray | 0 | 176 |
| Total, serious adverse events | Placebo Nasal Spray | 0 | 175 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21439168 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Mometasone Furoate Nasal Spray vs Placebo Nasal Spray: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00732381
GET https://conductscience.org/api/trials/v1/NCT00732381/registered